Sanofi (NASDAQ:SNY) Upgraded to “Strong-Buy” by StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a report published on Thursday morning.

Separately, Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Sanofi currently has a consensus rating of Moderate Buy and an average price target of $57.50.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $53.05 on Thursday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm’s 50-day moving average price is $49.51 and its two-hundred day moving average price is $48.69. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The stock has a market capitalization of $134.36 billion, a P/E ratio of 26.66, a P/E/G ratio of 1.50 and a beta of 0.59.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.95 EPS. As a group, sell-side analysts forecast that Sanofi will post 4.16 earnings per share for the current year.

Institutional Trading of Sanofi

Large investors have recently added to or reduced their stakes in the business. National Bank of Canada FI grew its stake in shares of Sanofi by 2.2% in the second quarter. National Bank of Canada FI now owns 358,440 shares of the company’s stock worth $17,719,000 after purchasing an additional 7,545 shares in the last quarter. Stablepoint Partners LLC lifted its holdings in Sanofi by 17.6% in the second quarter. Stablepoint Partners LLC now owns 23,704 shares of the company’s stock worth $1,235,000 after purchasing an additional 3,556 shares during the period. FSB Premier Wealth Management Inc. grew its position in Sanofi by 56.3% in the 2nd quarter. FSB Premier Wealth Management Inc. now owns 12,230 shares of the company’s stock valued at $593,000 after buying an additional 4,405 shares in the last quarter. Legacy Capital Wealth Partners LLC acquired a new position in Sanofi during the 2nd quarter valued at about $550,000. Finally, Fiera Capital Corp raised its position in shares of Sanofi by 9.5% during the 2nd quarter. Fiera Capital Corp now owns 40,195 shares of the company’s stock worth $1,950,000 after buying an additional 3,481 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.